Overview

Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV) Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV) Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correla

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University

Collaborator:

National Institutes of Health (NIH)